The startup develops novel chemical entities aimed at drug discovery for nonalcoholic steatohepatitis (NASH) and cardiovascular-metabolic diseases. By focusing on therapeutic candidates, the company enhances clinical outcomes for patients suffering from these conditions and related neurodegenerative diseases.
Funding
$19.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Nonalcoholic steatohepatitis (NASH) and cardiovascular-metabolic diseases present significant unmet medical needs due to their complex pathophysiology and limited treatment options. Current therapeutic approaches often fail to address the multiple factors contributing to disease progression, including liver fat accumulation, inflammation, and fibrosis. This results in suboptimal clinical outcomes and increased risk of complications such as cirrhosis, cardiovascular events, and neurodegenerative disorders.
Solution
TherasidBioscience is developing a pipeline of novel chemical entities (NCEs) designed to address the underlying mechanisms of NASH and related metabolic diseases. The company's approach involves a deep understanding of the cellular processes within the liver, focusing on the scientific analysis of how fat accumulation, inflammation, and fibrosis occur. By targeting different stages and mechanisms of action, TherasidBioscience aims to create therapeutic candidates that can be used as monotherapy or in combination to maximize efficacy. Their technology platform provides a means of evaluating novel and existing compounds, enhancing their expertise in NASH drug development.
Target Audience
The primary target audience includes patients suffering from NASH and related cardiovascular-metabolic diseases, as well as pharmaceutical companies seeking innovative therapeutic candidates for these conditions.
Features
- NASH platform focused on understanding cellular events within the liver
- Pipeline of NCEs targeting various stages of NASH development from early to clinical stages
- TB-840: Lead candidate in Phase 1 clinical trials
- Evaluation platform to assess the therapeutic potential of new and existing compounds
- Focus on identifying the root causes of liver fat accumulation, inflammation, and fibrosis
- Exploring combination therapies to maximize treatment efficacy